Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari, Daniela Pimentel-Maldonado, Jessica Stevens, Christine Phipps, Alice Hughes, Erica Lyons, Laura H Finkelstein, Monica A Munoz
{"title":"Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.","authors":"Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari, Daniela Pimentel-Maldonado, Jessica Stevens, Christine Phipps, Alice Hughes, Erica Lyons, Laura H Finkelstein, Monica A Munoz","doi":"10.1177/13524585251316518","DOIUrl":"https://doi.org/10.1177/13524585251316518","url":null,"abstract":"<p><strong>Background: </strong>Although gastrointestinal (GI) adverse reactions (ARs) were commonly observed in registrational clinical trials of fumarate acid ester (FAE) drugs for the treatment of multiple sclerosis, serious GI reactions were uncommon.</p><p><strong>Objective: </strong>The objective of the study is to describe the serious GI ARs that supported the post-market safety labeling change for FAE drugs.</p><p><strong>Methods: </strong>Review of the FDA Adverse Events Reporting System (FAERS) database and published medical literature was conducted to identify cases of serious GI events in patients taking FAE drugs.</p><p><strong>Results: </strong>Forty-nine cases of GI ARs with clinical events of perforation, ulceration, hemorrhage, or obstruction causally associated with FAE drug use were identified. Most cases occurred within 4 months of FAE drug initiation and required hospitalization. Ten of the cases required red blood cell transfusions, nine cases required surgical intervention, and two cases resulted in a fatal outcome.</p><p><strong>Conclusion: </strong>Review of postmarketing reports supported the identification of a class association between FAE drugs and serious GI ARs. As these reactions have implications for prescribing decisions and patient management, a safety labeling change was issued to add serious GI reactions to the Warnings and Precautions section of the prescribing information for FAE drugs.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251316518"},"PeriodicalIF":4.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"We need to engage representative patients' community rather than 'expert patients' to increase impact of research in the era of personalized medicine - Commentary.","authors":"Paola Zaratin","doi":"10.1177/13524585251315364","DOIUrl":"https://doi.org/10.1177/13524585251315364","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251315364"},"PeriodicalIF":4.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"YES We need to engage representative patients' community rather than 'expert patients' to increase impact of research in the era of personalised medicine.","authors":"Usman Khan","doi":"10.1177/13524585251315338","DOIUrl":"https://doi.org/10.1177/13524585251315338","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251315338"},"PeriodicalIF":4.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia
{"title":"Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.","authors":"Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia","doi":"10.1177/13524585251316471","DOIUrl":"https://doi.org/10.1177/13524585251316471","url":null,"abstract":"<p><strong>Background: </strong>Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.</p><p><strong>Objective: </strong>This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.</p><p><strong>Methods: </strong>We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.</p><p><strong>Results: </strong>TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.</p><p><strong>Discussion: </strong>Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251316471"},"PeriodicalIF":4.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andreu Vilaseca, Mar Tintoré, Pere Carbonell-Mirabent, Marta Rodríguez-Barranco, Mª Jesús Arévalo, Helena Ariño, Cristina Auger, Luca Bollo, René Carvajal, Joaquín Castilló, Alvaro Cobo-Calvo, Manuel Comabella, Victoria Fernández, Ingrid Galan, Luciana Midaglia, Neus Mongay-Ochoa, Carlos Nos, Susana Otero-Romero, Agustín Pappolla, Jordi Rio, Breogan Rodriguez-Acevedo, Jaume Sastre-Garriga, Sofía Sceppacuercia, Paula Tagliani, Carmen Tur, Angela Vidal-Jordana, Javier Villacieros-Álvarez, Ana Zabalza, Àlex Rovira, Xavier Montalban, Georgina Arrambide
{"title":"Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.","authors":"Andreu Vilaseca, Mar Tintoré, Pere Carbonell-Mirabent, Marta Rodríguez-Barranco, Mª Jesús Arévalo, Helena Ariño, Cristina Auger, Luca Bollo, René Carvajal, Joaquín Castilló, Alvaro Cobo-Calvo, Manuel Comabella, Victoria Fernández, Ingrid Galan, Luciana Midaglia, Neus Mongay-Ochoa, Carlos Nos, Susana Otero-Romero, Agustín Pappolla, Jordi Rio, Breogan Rodriguez-Acevedo, Jaume Sastre-Garriga, Sofía Sceppacuercia, Paula Tagliani, Carmen Tur, Angela Vidal-Jordana, Javier Villacieros-Álvarez, Ana Zabalza, Àlex Rovira, Xavier Montalban, Georgina Arrambide","doi":"10.1177/13524585251314749","DOIUrl":"https://doi.org/10.1177/13524585251314749","url":null,"abstract":"<p><strong>Background: </strong>It is essential to exclude alternative diagnoses to diagnose multiple sclerosis (MS). However, detailed descriptions of alternative diagnoses in patients with suspected MS presenting with clinically isolated syndrome (CIS) are limited.</p><p><strong>Objectives: </strong>To describe alternative diagnoses in patients presenting with CIS suggestive of MS.</p><p><strong>Methods: </strong>We conducted a descriptive analysis of patients from the Barcelona CIS cohort including subjects under 50 years of age with a CIS suggestive of MS but later diagnosed with conditions other than MS. We collected clinical, biological, and radiological data, and described the alternative etiologies identified.</p><p><strong>Results: </strong>Among 1468 patients in the Barcelona CIS cohort, 100 (6.8%) were diagnosed with an alternative condition. The most common neurological syndrome was optic neuritis (43.0%). Four patients (4.0%) had inflammatory-demyelinating lesions in at least two typical MS topographies on baseline magnetic resonance imaging (MRI), and 2 (2.0%) met the 2017 McDonald MS criteria. The most common etiologies were immune-mediated diseases (42.0%), especially MOGAD, followed by functional neurological disorders (15.0%) and vascular disease (10.0%).</p><p><strong>Conclusion: </strong>The range of alternative diagnoses encountered during the MS diagnostic process highlights the need to rule out better explanations than MS. However, current MS diagnostic criteria effectively identify patients without MS in this context.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251314749"},"PeriodicalIF":4.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty.","authors":"James F Sumowski, Joshua Sandry","doi":"10.1177/13524585241309805","DOIUrl":"https://doi.org/10.1177/13524585241309805","url":null,"abstract":"<p><strong>Background: </strong>Existing metrics of patient-reported cognitive difficulties in multiple sclerosis (MS) are lengthy, lack psychometric rigor, and/or fail to query prevalent expressive language deficits.</p><p><strong>Objective: </strong>Develop a brief psychometrically robust metric of patient-reported cognitive deficits that includes language items; the Multiple Sclerosis Cognitive Scale (MSCS).</p><p><strong>Method: </strong>Exploratory factor analysis (EFA) was conducted on 20 Perceived Deficits Questionnaire (PDQ) items plus five newly developed language questions in a large MS sample and matched respondents without neurologic disease. Independent confirmatory principal components analysis (PCA) assessed EFA factor structure. Reliability of the new scale and subscales, and relationships with objective cognitive impairment and cognitive change, were assessed.</p><p><strong>Results: </strong>EFA in patients (<i>n</i> = 502) and controls (<i>n</i> = 350), item analyses, and confirmatory PCA in an independent sample (<i>n</i> = 361 patients; 150 controls) supported construction of an eight-item scale with four two-item subscales: Executive/Speed, Working Memory, Expressive Language, and Episodic Memory. Internal consistency and test-retest reliability were excellent for the total MSCS (<i>α</i> = 0.93, ICC = 0.95) and good for each subscale (<i>α</i>'s:0.83-0.87; ICCs: 0.86-0.92). MSCS showed medium-size links to cross-sectional objective cognitive impairment (<i>η</i><sup>2</sup> = .06) and cognitive change over time (<i>η</i><sup>2</sup> = .07); the traditional PDQ did not (<i>η</i><sup>2</sup>s = 0.01 and 0.02).</p><p><strong>Conclusion: </strong>The brief MSCS is a psychometrically robust, reliable, and valid metric of patient-reported cognitive deficits in MS that holds promise for improving assessment of MS cognitive dysfunction.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241309805"},"PeriodicalIF":4.8,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christine Lebrun-Frenay, Sandrine Kerbrat, Darin T Okuda, Cassandre Landes-Chateau, Orhun H Kantarci, Chloe Pierret, Erwan Drezen, Emmanuel Nowak, Aksel Siva, Christina J Azevedo, Mikael Cohen, Emmanuelle Leray
{"title":"Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome.","authors":"Christine Lebrun-Frenay, Sandrine Kerbrat, Darin T Okuda, Cassandre Landes-Chateau, Orhun H Kantarci, Chloe Pierret, Erwan Drezen, Emmanuel Nowak, Aksel Siva, Christina J Azevedo, Mikael Cohen, Emmanuelle Leray","doi":"10.1177/13524585241291471","DOIUrl":"10.1177/13524585241291471","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have shown that people with multiple sclerosis (MS) had frequent healthcare visits up to 10 years before being diagnosed but with no information from magnetic resonance imaging (MRI) scans of the connection with the radiologically isolated syndrome (RIS).</p><p><strong>Objective: </strong>To analyze healthcare use 3 years before the RIS diagnosis.</p><p><strong>Methods: </strong>We examined healthcare usage before the first scan in RIS cases from 2010 to 2019. RIS subjects were identified from the French National MS observatory and compared to the general population (matched 10:1) and MS patients (matched 4:1).</p><p><strong>Results: </strong>Among 482 RIS individuals, 223 (46.3%) were not linked to the healthcare resources database. The remaining RIS individuals (53.7%) had higher healthcare usage before their RIS diagnosis for issues related to neurology visits, headaches (odds ratio (OR): 3.34, confidence interval (CI): [2.00-5.57], <i>p</i> < 0.0001), and the use of anti-migraine drugs (OR: 2.61, CI: [1.37-4.99], <i>p</i> = 0.004) compared to MS.</p><p><strong>Conclusion: </strong>Only about half of RIS patients had MS-selected healthcare resources, which allowed for data linkage. Those who did seek care before their RIS diagnosis were most commonly known for other neurological comorbidities. These findings do not support the idea of a systemic prodrome before RIS diagnosis.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"184-196"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Cacciaguerra, Loredana Storelli, Elisabetta Pagani, Paolo Preziosa, Sharlota Mesaros, Vittorio Martinelli, Lucia Moiola, Marta Radaelli, Jovana Ivanovic, Olivera Tamas, Jelena Drulovic, Massimo Filippi, Maria A Rocca
{"title":"Use of brain MRI and gene expression atlases to reconstruct the pathophysiology of autoimmune neurological disorders: The proof-of-concept of NMOSD.","authors":"Laura Cacciaguerra, Loredana Storelli, Elisabetta Pagani, Paolo Preziosa, Sharlota Mesaros, Vittorio Martinelli, Lucia Moiola, Marta Radaelli, Jovana Ivanovic, Olivera Tamas, Jelena Drulovic, Massimo Filippi, Maria A Rocca","doi":"10.1177/13524585241307154","DOIUrl":"10.1177/13524585241307154","url":null,"abstract":"<p><strong>Background: </strong>The understanding of disease pathophysiology is pivotal for tailored treatments. The spatial distribution of brain damage relies on the regional antigen expression and the local balance of susceptibility and protective elements.</p><p><strong>Objective: </strong>As proof-of-concept, we investigated the spatial association between brain damage and gene expression in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD).</p><p><strong>Methods: </strong>In this multicenter cross-sectional study, 90 AQP4 + NMOSD patients and 94 age-matched healthy controls underwent a brain magnetic resonance imaging (MRI). We used T2-hyperintense lesion probability maps and white/gray matter atrophy as proxies of inflammation and neurodegeneration. The association with the expression of 266 candidate genes was obtained with the Multimodal Environment for Neuroimaging and Genomic Analysis platform. A functional-enrichment analysis investigated overrepresented biological processes.</p><p><strong>Results: </strong>In AQP4 + NMOSD, T2-hyperintense lesions were mainly periventricular; atrophy mostly involved the visual pathway. The expression of AQP4 and complement (C4a and C5) was associated with both inflammation and neurodegeneration. Complement activation and regulation/uptake of the insulin-like growth factor were the most relevant enriched pathways. Nonspecific pathways related to DNA synthesis and repair were associated with brain atrophy.</p><p><strong>Conclusions: </strong>Quantitative MRI and gene expression atlas identified the key elements of AQP4 + NMOSD pathophysiology. This analysis could help in understanding the pathophysiology of antibody-mediated autoimmune disorders.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":"31 2","pages":"140-158"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision.","authors":"Jorge Correale, Mariano Marrodan","doi":"10.1177/13524585241305956","DOIUrl":"10.1177/13524585241305956","url":null,"abstract":"<p><p>Live-attenuated vaccines provide robust immunity against diseases like tuberculosis, measles, mumps, rubella, polio, yellow fever, dengue, typhoid fever, and varicella, with just one or a few doses. However, concerns arise regarding potential pathogen reversion to virulence, which is particularly risky for immunocompromised individuals, contraindicating their administration in multiple sclerosis (MS) patients under modified disease treatments due to the possibility of triggering infections, or stimulating the immune system, precipitating new exacerbations. On the contrary, these vaccines offer enduring immunity that is crucial for protecting MS patients from endemic infectious diseases, leading to severe complications if contracted. These concerns underscore the complex balance between vaccination benefits and the risks of exacerbating MS in patients residing in regions with endemic diseases. This review explores the challenges and considerations associated with their use in MS patients, aiming to maximize benefits while minimizing risks.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"131-139"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leila Simani, Ceren Tozlu, Seonjoo Lee, Jordan Dworkin, Alexander S Ratzan, Korhan Buyukturkoglu, Kaho Onomichi, Jennie Mata, Claire S Riley, Victoria M Leavitt
{"title":"Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model.","authors":"Leila Simani, Ceren Tozlu, Seonjoo Lee, Jordan Dworkin, Alexander S Ratzan, Korhan Buyukturkoglu, Kaho Onomichi, Jennie Mata, Claire S Riley, Victoria M Leavitt","doi":"10.1177/13524585241303491","DOIUrl":"10.1177/13524585241303491","url":null,"abstract":"<p><strong>Background: </strong>Memory decline is common in multiple sclerosis (MS), although pathophysiological mechanisms are not fully understood.</p><p><strong>Objective: </strong>The objective was to investigate the relationship of changes in structural and functional neuroimaging markers to memory decline over 3-year follow-up.</p><p><strong>Methods: </strong>Participants with MS underwent cognitive evaluation and structural, diffusion, and functional 3T magnetic resonance imaging (MRI) scans at baseline and 3-year follow-up. Changes in neuroimaging metrics from baseline to follow-up were compared between memory stable and memory decline groups. Our hypothesis that structural and functional connectivity changes mediate the association of atrophy to memory decline was tested.</p><p><strong>Results: </strong>A total of 249 MS patients completed baseline visit; 169 (67.8%) returned at 3-year follow-up. Based on ⩾10% decline, memory decline was observed in 44.4% (<i>n</i> = 75). Those with memory decline showed marginally greater whole-brain volume loss over time compared with those with stable memory performance (<i>p</i> = 0.08). In those with memory decline, changes in white matter tract integrity were related to regional cortical thinning (<i>p</i> < 0.01). Exploratory mediation analysis revealed structural and functional connectivity to mediate the relationship of atrophy to verbal and visual memory decline.</p><p><strong>Conclusion: </strong>Further work is needed to characterize complex interrelationships of atrophy and structural/functional connectivity changes to memory decline in MS.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"207-217"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}